<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophr Bull</journal-id><journal-id journal-id-type="iso-abbrev">Schizophr Bull</journal-id><journal-id journal-id-type="publisher-id">schbul</journal-id><journal-title-group><journal-title>Schizophrenia Bulletin</journal-title></journal-title-group><issn pub-type="ppub">0586-7614</issn><issn pub-type="epub">1745-1701</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5887711</article-id><article-id pub-id-type="doi">10.1093/schbul/sby015.215</article-id><article-id pub-id-type="publisher-id">sby015.215</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>O5. Oral Session: Comorbidity</subject></subj-group></subj-group></article-categories><title-group><article-title>O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vermeulen</surname><given-names>Jentien</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>van Rooijen</surname><given-names>Geeske</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>van de Kerkhof</surname><given-names>Marita</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Sutterland</surname><given-names>Arjen</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Correll</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>de Haan</surname><given-names>Lieuwe</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Academic Medical Center, University of Amsterdam</aff><aff id="AF0002"><label>2</label>Zucker Hillside Hospital, Hofstra North Shore LIJ School of Medicine</aff><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><pub-date iso-8601-date="2018-04-01" pub-type="epub"><day>01</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>44</volume><issue>Suppl 1</issue><issue-title>Abstracts for the Sixth Biennial SIRS Conference</issue-title><fpage>S86</fpage><lpage>S86</lpage><permissions><copyright-statement>&#x000a9; Maryland Psychiatric Research Center 2018.</copyright-statement><copyright-year>2018</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="sby015.215.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Patients with schizophrenia have a high mortality risk. The role of clozapine in the long-term mortality risk is insufficiently known. The objectives of the current study were to determine in i) all-cause long-term mortality rates and ii) specific-cause mortality rates and ratios in patients with schizophrenia with and without clozapine treatment.</p></sec><sec id="s2"><title>Methods</title><p>We systematically searched EMBASE, MEDLINE and PsycINFO and included studies that used a long-term follow-up design (i.e., &#x02265;52 weeks) and reported on mortality in adults diagnosed with schizophrenia-spectrum disorders receiving clozapine treatment.</p></sec><sec id="s3"><title>Results</title><p>Altogether, 23 studies fulfilled our criteria, reporting on 1,166 deaths during 203,231 patient years for patients treated with clozapine. Pooling five cohort studies that included sufficient sample sizes and length of follow-up, we found an unadjusted mortality rate of 7.34 per 1,000 patient years (95%CI=4.39&#x02013;10.28). Long-term, crude mortality rate ratios were significantly lower in patients treated with clozapine compared to patients without clozapine treatment (mortality rate ratio=0.59, 95%CI=0.43&#x02013;0.81, p-value&#x0003c;0.001) as well as compared to other antipsychotic medications (mortality rate ratio=0.61, 95%CI=0.45&#x02013;0.84, p-value=0.002). We found incomplete and inconsistent reporting of specific-cause mortality rates. Statistical heterogeneity was high in all analyses.</p></sec><sec id="s4"><title>Discussion</title><p>Future studies with substantial length of follow-up and uniform reporting of confounders are needed to validate these findings of a significantly lower mortality risk in patients using clozapine, in particular for the risk of cardiovascular mortality.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>